ERBB2 and sarcoma: Pediatric patients have also been treated with CAR T cells targeting HER2 (sarcomas and glioblastoma) and L1CAM (neuroblastoma), and definite signs of clinical activity have been observed in recent studies (N. Ahmed et al. 2015, Pinto et al. 2018).